Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Allogene Therapeutics Inc. (NASDAQ:ALLO) is making waves as one of the best biotech penny stocks to buy in 2026. Recently, the company closed a successful underwritten public offering, raising an impressive $200.4 million in aggregate gross proceeds. This offering included 87.5 million shares of common stock priced at $2.00 per share, along with an additional 12.7 million shares purchased through a partial exercise of the underwriters’ option.
A syndicate of financial institutions, led by Goldman Sachs & Co. LLC, Jefferies, and TD Cowen, facilitated the transaction. The company plans to utilize the net proceeds for various purposes, including clinical trial expenses, ongoing research and development, general administrative costs, and capital expenditures. This financial boost positions Allogene Therapeutics Inc. to advance its pipeline of off-the-shelf chimeric antigen receptor T-cell (CAR T) therapies.
The offering was conducted under an existing shelf registration statement that became effective in April 2024. Following the closing, the company’s common stock experienced a slight decrease in trading. Joint bookrunners for the deal also included Piper Sandler and William Blair, with additional support from Baird, Canaccord Genuity, and TPG Capital BD, LLC.
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s objective is to provide a scalable and readily available cell therapy derived from healthy donors.
While ALLO shows promise as an investment, there are other opportunities in the AI sector that may offer greater upside potential with lower downside risk. For investors seeking undervalued AI stocks poised to benefit from current market trends, exploring alternative options may be worthwhile.
In conclusion, Allogene Therapeutics Inc. continues to make strides in the biotech sector with its innovative approach to CAR-T cell therapy. The recent public offering has provided the company with the financial resources needed to further develop its pipeline and bring potentially life-saving treatments to market. As the company continues to grow and expand its reach, investors will be closely watching for future developments and advancements in the field of biotechnology.
